NEW YORK (GenomeWeb News) – Investment analysts have weighed in on the US Food and Drug Administration's clearance of Gen-Probe's Aptima HPV assay, saying that they expect a modest revenue contribution in 2012 but a potentially significant ramp in sales over the following two years.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.